Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.
Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Schuhmacher C, Urba S, van de Velde C, Walsh TN, Ychou M, Jensen K. Ronellenfitsch U, et al. Among authors: niedzwiecki d. Eur J Cancer. 2013 Oct;49(15):3149-58. doi: 10.1016/j.ejca.2013.05.029. Epub 2013 Jun 22. Eur J Cancer. 2013. PMID: 23800671 Review.
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U, Jensen K, Seide S, Kieser M, Schwarzbach M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Piessen G, Schuhmacher C, Urba S, van de Velde C, Ychou M, Hofheinz R, Lorenzen S. Ronellenfitsch U, et al. Among authors: niedzwiecki d. Eur J Cancer. 2019 Dec;123:101-111. doi: 10.1016/j.ejca.2019.10.001. Epub 2019 Nov 1. Eur J Cancer. 2019. PMID: 31678767 Free PMC article.
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Schuhmacher C, Urba S, van de Velde C, Walsh TN, Ychou M, Jensen K. Ronellenfitsch U, et al. Among authors: niedzwiecki d. Eur J Surg Oncol. 2017 Aug;43(8):1550-1558. doi: 10.1016/j.ejso.2017.05.005. Epub 2017 May 18. Eur J Surg Oncol. 2017. PMID: 28551325
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. Kelsen D, et al. Among authors: niedzwiecki d. Cancer. 1991 Sep 1;68(5):965-9. doi: 10.1002/1097-0142(19910901)68:5<965::aid-cncr2820680509>3.0.co;2-2. Cancer. 1991. PMID: 1833042 Clinical Trial.
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S. Kosumi K, et al. Among authors: niedzwiecki d. Eur J Cancer. 2019 Apr;111:82-93. doi: 10.1016/j.ejca.2019.01.022. Epub 2019 Mar 1. Eur J Cancer. 2019. PMID: 30826660 Free PMC article.
324 results